Edition:
United States

People: Adaptimmune Therapeutics PLC (ADAP.OQ)

ADAP.OQ on NASDAQ Stock Exchange Global Select Market

3.50USD
15 Jul 2019
Change (% chg)

-- (--)
Prev Close
$3.50
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
74,770
52-wk High
$14.52
52-wk Low
$3.20

Tayton-Martin, Helen 

Dr. Helen Katrina Tayton-Martin, Ph.D., M.B.A, serves as Chief Business Officer of the Company. She was Chief Operating Officer of the Company. Dr. Tayton-Martin has 25 years of experience working within the pharma, biotech and consulting environment in disciplines across preclinical and clinical development, outsourcing, strategic planning, due diligence and business development. She formerly served as Chief Operating Officer and is a co-founder of Adaptimmune, joining from Avidex Limited (subsequently Medigene) where she was responsible for commercial development of the soluble TCR program in cancer and HIV therapy. Dr. Tayton-Martin holds a Ph.D. in molecular immunology from the University of Bristol, U.K. and an M.B.A. from London Business School.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Awards, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --